Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH5 | P11766 | 1/20 | 0.36 |
| ▸ | CD38 | P28907 | 4/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.33 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848916 | 0.93 | CD38 (0.36) | ADH5CD38ROCK2CRBNHDAC1 | |
| SCHEMBL12848744 | 0.92 | ADH5 (0.36) | ADH5CD38ROCK2CRBNHDAC1 | |
| SCHEMBL12848915 | 0.90 | MAPT (0.36) | MAPT | |
| SCHEMBL12848750 | 0.90 | CD38 (0.34) | ADH5CD38ROCK2CRBNHDAC1 | |
| SCHEMBL12848747 | 0.90 | CD38 (0.38) | ADH5CD38CRBNTAOK1TAOK3 | |
| SCHEMBL12848746 | 0.88 | TNIK (0.37) | ADH5CD38CRBNHDAC1CSF1R | |
| SCHEMBL12848470 | 0.87 | CASP6 (0.32) | ADH5CD38MAPTCRBN | |
| SCHEMBL12848462 | 0.87 | NPC1 (0.40) | ADH5CD38HDAC1CYP3A4CSF1R | |
| SCHEMBL12848565 | 0.87 | CSF1R (0.37) | ADH5CD38ABL1CRBNHDAC1 | |
| SCHEMBL12848748 | 0.85 | ABL1 (0.38) | ABL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009089305-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | ADH5 3303/4885CD38 583/4885ABL1 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.